A Single-centre Study Evaluating the Safety of ViscoGel and Its Safety and Efficacy as an Adjuvant in Act-HIB Vaccine Administered by Intramuscular Injection to Healthy Volunteers in a Single-blind Randomised, Parallel-group Design

Trial Profile

A Single-centre Study Evaluating the Safety of ViscoGel and Its Safety and Efficacy as an Adjuvant in Act-HIB Vaccine Administered by Intramuscular Injection to Healthy Volunteers in a Single-blind Randomised, Parallel-group Design

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2013

At a glance

  • Drugs Chitosan-based adjuvant (Primary) ; Hib vaccine conjugate
  • Indications Haemophilus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 15 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported ClinicalTrials.gov.
    • 23 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top